Colorado Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Colorado Health Reporter.

Press releases published on June 22, 2026

Jun. 22, 2026

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Indeterminate GlobeNewswire

Jun. 22, 2026

Medidata Unveils New Academic Board to Bridge the Gap Between Research and Patient Care

Indeterminate GlobeNewswire

Jun. 22, 2026

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Indeterminate GlobeNewswire

Jun. 22, 2026

Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure

Indeterminate GlobeNewswire

Jun. 22, 2026

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

Indeterminate GlobeNewswire

Jun. 22, 2026

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Indeterminate GlobeNewswire

Jun. 22, 2026

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

Indeterminate GlobeNewswire

Jun. 22, 2026

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

Indeterminate GlobeNewswire

Jun. 22, 2026

Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis

Indeterminate GlobeNewswire

Jun. 22, 2026

Catheter Precision, Inc. Announces Allowance of Key Intellectual Property

Indeterminate GlobeNewswire

Jun. 22, 2026

Route 92 Medical Announces First Commercial Cases in Canada

Indeterminate GlobeNewswire

Jun. 22, 2026

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

Indeterminate GlobeNewswire

Jun. 22, 2026

TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke

Indeterminate GlobeNewswire

Jun. 22, 2026

BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives

Indeterminate GlobeNewswire

Jun. 22, 2026

NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

Indeterminate GlobeNewswire

Jun. 22, 2026

MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder

Indeterminate GlobeNewswire

Jun. 22, 2026

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

Indeterminate GlobeNewswire

Jun. 22, 2026

Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031

Indeterminate GlobeNewswire

Jun. 22, 2026

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

Indeterminate GlobeNewswire

Jun. 22, 2026

QTREX Announces Management Share Purchase Plan

Indeterminate GlobeNewswire